Is a Fetus a Living Entity? Reframing the Question of Its Right to Survive in Contemporary Maternal–Fetal Medicine
Year: 2026
Type: article
Abstract: To editor, We read with continued interest the ongoing ethical and clinical debates surrounding the moral and legal status of the fetus, particularly in the context of rapidly advancing maternal–fetal medicine. While the question of whether a fetus is a living entity is not new, we argue that the more pressing contemporary issue is how evolving medical capabilities are reshaping the meaning, scope, and limits of any claimed fetal “right to survive.” In current clinical practice, advances in fetal imaging, intrauterine interventions, and neonatal intensive care have significantly altered the landscape of perinatal decision-making. Procedures such as fetal surgery and targeted intrauterine therapies, along with improved survival of extremely preterm neonates, have progressively shifted the limits of viability.1 However, these developments have not been matched by equivalent clarity in ethical frameworks or legal standards. Instead, they have exposed important knowledge gaps and disparities, particularly between high-resource settings and low- and middle-income countries (LMICs), where access to advanced neonatal care remains limited, and survival at the threshold of viability is less certain.1 This disparity raises two critical questions: if the capacity for fetal survival increasingly depends on technological availability rather than intrinsic biological thresholds, can viability continue to serve as a stable benchmark for determining the legal and ethical status of the fetus? Furthermore, does expanding technological capability strengthen claims of fetal rights, or does it instead complicate the balance between fetal interests and maternal autonomy?2 Here, we revisit the question of fetal life and survival not as a static philosophical issue, but as a dynamic clinical and ethical challenge shaped by technological progress, resource inequality, and evolving societal values. We specifically focus on the emerging tensions between biological life, clinical viability, and the ethical and legal boundaries that define the extent—if any—of a fetus’s right to survive. We acknowledge that, from a biological standpoint, the fetus is unequivocally a living organism, characterized by continuous growth, cellular differentiation, and metabolic activity throughout gestation. However, we emphasize that biological life alone does not determine moral status or confer legal rights. Instead, contemporary maternal–fetal medicine relies on clinically meaningful constructs—most notably fetal viability—to bridge the gap between biological existence and ethical or legal consideration. Viability is generally defined as the capacity of a fetus for sustained survival outside the uterus with appropriate medical support. In high-resource settings, this threshold is commonly placed at approximately 22–24 weeks of gestation, although survival at this stage remains uncertain and is closely linked to the availability and quality of neonatal intensive care.1 Importantly, we note that this threshold is not biologically fixed but is highly dependent on technological capability and clinical expertise. This variability becomes particularly evident when comparing high-income countries with LMICs. In many LMIC settings, limited access to advanced neonatal care, trained personnel, and infrastructure shifts the practical threshold of survival to later gestational ages.1 Consequently, what may be considered a “viable fetus” in one context may not be so in another. We argue that this disparity exposes a fundamental limitation of viability as a universal standard, given that it reflects healthcare inequality as much as it does fetal developmental capacity. Reliance on viability as a threshold for determining the legal and ethical status of a fetus introduces further complexity. Viability has historically served as a reference point in abortion jurisprudence and fetal protection frameworks; however, its dependence on evolving medical technology renders it conceptually unstable.2 As Romanis has argued, viability is not an intrinsic property of the fetus but a relational concept contingent on external support systems.2 We therefore contend that viability should be understood not as a definitive boundary, but as a fluid and context-dependent threshold that informs, rather than determines, ethical obligations. While it remains a useful clinical guide, its variability limits its ability to serve as a clear moral or legal dividing line. This ambiguity sets the stage for a more challenging question: where should the ethical “borderline” and legal “bottom line” be drawn when balancing fetal interests with maternal autonomy? We recognize that the moral status of the fetus remains one of the most contested issues in bioethics, with no universal agreement on when, or to what extent, moral consideration should be accorded. Some perspectives attribute moral status from early developmental stages based on biological continuity, while others argue that moral significance accrues gradually throughout gestation, often in relation to viability or functional capacities, such as neurological development. These divergent views highlight the absence of a single, definitive moral threshold. In clinical practice, however, we find that abstract philosophical debates are often less helpful than pragmatic ethical frameworks. The concept of the fetus as a patient, as articulated by Chervenak and McCullough, provides a clinically relevant approach that allows ethical obligations to be understood within the context of care.3 According to this framework, the fetus acquires patient status when it is presented for medical intervention and when beneficence-based obligations toward fetal well-being can be reasonably justified—particularly as viability approaches or is achieved.3 Importantly, this approach does not require assigning full independent moral status to the fetus at all stages of gestation. Rather, it situates fetal interests within the maternal–fetal dyad, where ethical responsibilities are inherently relational and must be balanced against the autonomy, health, and well-being of the pregnant woman. In this context, we propose a useful distinction between the ethical “borderline” and the legal “bottom line.” The ethical borderline is inherently flexible and context-sensitive. It evolves with gestational age, clinical viability, maternal preferences, and anticipated outcomes. For example, before viability, fetal moral status may largely depend on the pregnant woman’s values and willingness to pursue fetal-directed interventions. After viability, however, the ethical weight accorded to fetal interests tends to increase because of the realistic possibility of extrauterine survival.3,4 In contrast, the legal bottom line is typically more rigid and defined by jurisdictional frameworks. Legal systems often rely on constructs such as the “born alive” rule, whereby full legal personhood—and the associated rights—are recognized only after live birth.2 This creates a clear legal boundary, even though it may not fully align with evolving clinical realities, particularly in cases where a fetus demonstrates the capacity for survival before birth. We argue that the tension between these two constructs—an evolving ethical borderline and a fixed legal bottom line—represents a central challenge in contemporary maternal–fetal medicine. Advances in intrauterine therapy and neonatal care continue to blur traditional boundaries, yet legal definitions often lag behind these developments. This misalignment may result in ethical uncertainty for clinicians, particularly when managing cases at the threshold of viability or when maternal and fetal interests diverge. Emerging empirical evidence suggests that clinicians themselves often adopt a gradualist approach, recognizing that fetal moral significance increases over time rather than appearing at a single fixed point. Notably, such assessments are frequently grounded in clinical viability and professional judgment rather than abstract criteria such as sentience alone.4 This reinforces the need for a flexible ethical framework that can accommodate both medical realities and patient-centered values. Accordingly, we emphasize that neither ethical reasoning nor legal standards can rely on a single definitive threshold for fetal rights. Instead, clinical decision-making must navigate the space between a shifting ethical boundary and a relatively fixed legal framework, requiring careful judgment, transparent communication, and respect for maternal autonomy. We argue that, even if the fetus is accepted as a biologically living entity, the attribution of an independent “right to survive” cannot be considered absolute. Rights, in both ethical and legal frameworks, are not derived solely from biological existence but are shaped by considerations of autonomy, relational context, and societal recognition. From a legal standpoint, many jurisdictions continue to rely on the “born alive” principle as the threshold for personhood. Under this framework, a fetus acquires full legal recognition only after demonstrating signs of life following birth, regardless of its prior developmental capacity.2 While this creates a clear legal boundary, it does not fully reflect contemporary clinical realities, particularly in cases where a fetus has a demonstrable capacity for survival before delivery. In contrast, clinical practice in maternal–fetal medicine adopts a more nuanced and graduated approach. Once viability is approached or achieved, clinicians increasingly recognize beneficence-based obligations toward fetal well-being, particularly when interventions may improve survival without imposing disproportionate risk on the pregnant woman.3 Nevertheless, these obligations arise only within the maternal–fetal relationship and do not constitute independent or overriding fetal rights. In practical terms, modern obstetric care routinely incorporates interventions aimed at improving fetal survival, including antenatal corticosteroid administration, tocolysis, intensive fetal monitoring, and, where appropriate, planned preterm delivery in controlled settings.5 In selected cases, advances in intrauterine therapy—such as fetal surgery or targeted medical interventions—have further expanded the scope of fetal-directed care. These developments reinforce the clinical relevance of fetal interests, particularly at later gestational stages. Simultaneously, we emphasize that such interventions are ethically justified only when they align with maternal informed consent and do not expose the pregnant woman to undue harm. The ethical principle of respect for autonomy remains central, and no fetal interest can be pursued in isolation from the rights and well-being of the pregnant patient. This leads us to a critical conclusion: while the possibility of survival strengthens ethical consideration for the fetus, it does not translate into an enforceable or absolute right to survive. Instead, what emerges is a conditional and context-dependent ethical obligation, shaped by gestational age, clinical feasibility, maternal choice, and anticipated outcomes. We further note that cultural and healthcare system factors may influence how these obligations are interpreted. In resource-limited settings, where neonatal survival at early gestational ages is less certain, aggressive fetal-directed interventions may not always be feasible or ethically justified.1 This again highlights that the notion of a “right to survive” cannot be separated from real-world clinical contexts and resource availability. Accordingly, we contend that the concept of fetal survival is best understood not as a fixed right, but as a relational and clinically mediated interest, which gains ethical weight with advancing gestation but remains inherently balanced against maternal autonomy and well-being. We emphasize that ethical decision-making in maternal–fetal medicine ultimately depends on achieving a careful balance between respect for maternal autonomy and consideration of fetal interests. Pregnancy is inherently relational, and the fetus cannot be ethically or clinically separated from the pregnant woman. Accordingly, we argue that maternal autonomy must remain the foundational principle guiding all medical decisions, particularly before viability. However, we also recognize that fetal interests gain increasing ethical significance as gestation progresses and the possibility of survival becomes more realistic. This evolving significance is consistent with the concept of the fetus as a patient, wherein beneficence-based obligations emerge progressively rather than absolutely.3,4 However, these obligations do not justify coercive interventions or the subordination of maternal rights. Instead, they support a model of shared decision-making, grounded in informed consent, clinical judgment, and individualized care. In situations involving severe fetal anomalies, extreme prematurity, or maternal health risks, ethical practice may support a spectrum of options, including expectant management, palliative approaches, or pregnancy termination within applicable legal frameworks.6 Such decisions are inherently complex and must account for medical feasibility, anticipated outcomes, and the values and preferences of the pregnant patient. Revisiting the distinction proposed earlier, we conclude that the ethical “borderline” in maternal–fetal medicine is dynamic, shaped by gestational age, viability, clinical context, and maternal choice. In contrast, the legal “bottom line” remains relatively fixed, often anchored in the recognition of personhood only after live birth.2 The divergence between these two constructs is likely to widen as advances in intrauterine therapy and neonatal care continue to extend the possibility of survival to earlier gestational ages. In conclusion, while the fetus is undeniably a biologically living entity, we contend that this status alone does not establish an independent or absolute right to survive. Instead, fetal survival should be understood as a context-dependent ethical interest, which increases with clinical viability but remains inseparable from the rights, health, and autonomy of the pregnant woman. A rigid, one-dimensional framework is therefore inadequate. We propose that a relational, gestationally sensitive, and clinically grounded approach offers the most practical way forward. Such a framework accommodates evolving medical capabilities while preserving ethical clarity, minimizing conflict, and ensuring that care remains patient-centered. As maternal–fetal medicine continues to advance, ongoing ethical reflection will be essential to align clinical practice with both human values and legal realities. Funding None. Author Contributions Both authors (Pragnesh Parmar, Gunvanti Rathod) contributed equally to the preparation of this manuscript. Conflicts of Interest None. Data Availability The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Source: Maternal-Fetal Medicine
Authors: Pragnesh Parmar, Gunvanti Rathod
Institution: All India Institute of Medical Sciences Bibinagar
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7160519030